Latest news and press releases about Artiva Biotherapeutics, Inc. (ARTV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy.
Price
| Price | $8.60 |
| Market Cap | $420M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.98 |
| EV / EBITDA | -2.38 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -53.86% |
| Return on Invested Capital | -26.91% |
| Return on Assets | -24.64% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · CNTB · DTIL · GUTS · IFRX · MGX
Explore sector: Healthcare · Biotechnology
More sections of ARTV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks